Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT – Get Free Report) declared that its board has approved a share repurchase program on Monday, November 16th, RTT News reports. The company plans to repurchase $54.95 million in outstanding shares. This repurchase authorization allows the biotechnology company to buy up to 2.5% of its shares through open market purchases. Share repurchase programs are usually an indication that the company’s leadership believes its shares are undervalued.
Wall Street Analysts Forecast Growth
Several research firms have weighed in on LKFT. Morgan Stanley boosted their target price on shares of Lakefront Biotherapeutics American Depositary Shares from $26.00 to $27.00 and gave the company an “equal weight” rating in a research note on Monday. Weiss Ratings upgraded shares of Lakefront Biotherapeutics American Depositary Shares from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, October 2nd. Raymond James Financial reaffirmed a “market perform” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a report on Thursday. TD Cowen assumed coverage on shares of Lakefront Biotherapeutics American Depositary Shares in a report on Friday. They issued a “strong-buy” rating for the company. Finally, Royal Bank Of Canada raised shares of Lakefront Biotherapeutics American Depositary Shares from a “sector perform” rating to an “outperform” rating and boosted their price objective for the company from $26.00 to $45.00 in a research report on Wednesday, September 23rd. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $36.00.
Read Our Latest Stock Analysis on LKFT
Lakefront Biotherapeutics American Depositary Shares Price Performance
Shares of NASDAQ LKFT traded up $0.81 during mid-day trading on Monday, hitting $34.79. The company had a trading volume of 292,601 shares, compared to its average volume of 265,015. The stock has a market cap of $2.29 billion, a price-to-earnings ratio of -24.67 and a beta of 0.22. Lakefront Biotherapeutics American Depositary Shares has a 12 month low of $25.68 and a 12 month high of $36.24. The firm’s 50 day simple moving average is $30.49 and its two-hundred day simple moving average is $29.94.
Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT – Get Free Report) last released its quarterly earnings data on Wednesday, November 11th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter. The company had revenue of $7.87 million during the quarter. Equities analysts forecast that Lakefront Biotherapeutics American Depositary Shares will post -1.46 earnings per share for the current year.
Lakefront Biotherapeutics American Depositary Shares News Roundup
Investors following LKFT have been watching these news items:
- Positive Sentiment: Lakefront launched a new buyback of up to €50 million after completing its previous €50 million program. The company says it may repurchase up to 2.5% of its shares, a move that can signal management confidence and support demand for the stock. Lakefront Initiates New €50 Million Share Repurchase Program
- Positive Sentiment: TD Cowen initiated coverage with a “strong buy” rating, adding a bullish analyst view. TD Cowen coverage reported by Zacks
- Negative Sentiment: Morgan Stanley raised its price target from $26 to $27 but kept an “equal weight” rating. The target remains about 22.4% below the cited share price, suggesting the firm sees downside from current levels.
Lakefront Biotherapeutics American Depositary Shares Company Profile
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company’s pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis.
Read More
- Five stocks we like better than Lakefront Biotherapeutics American Depositary Shares
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Lakefront Biotherapeutics American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lakefront Biotherapeutics American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.
